AYTU BIOPHARMA, INC Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
AYTU BIOPHARMA, INC (AYTU) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2026-09-22
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-12-31 was $0.02.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-09-30 was $0.06.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2023-12-31 was -$0.15.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2023-09-30 was -$0.12.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2025 was $0.10.
- AYTU BIOPHARMA, INC income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2024 was -$0.60.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-K · filed 2026-09-22 | ||
| 2025-06-30 | $0.10 10-K · filed 2026-09-22 | ||
| 2024-12-31 | $0.02 10-Q · filed 2025-02-12 | $0.08 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $0.06 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | -$0.60 10-K · filed 2025-09-23 | ||
| 2023-12-31 | -$0.15 10-Q · filed 2025-02-12 | -$0.27 10-Q · filed 2025-02-12 | |
| 2023-09-30 | -$0.12 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |